Technology | September 08, 2014

iCAD Expands Partnership With Volpara Solutions to Offer Enhanced Breast Imaging Analytics for 2-D Mammography and Tomosynthesis

New additions to PowerLook AMP provide radiologists a consistent, standardized way to evaluate performance of breast imaging systems in real time

September 8, 2014 — iCAD Inc. announced that, in addition to Volpara Density volumetric breast density assessment software, Volpara Analytics and Volpara Dose solutions are now available as part of iCAD’s PowerLook Advanced Mammography Platform (AMP). With the addition of these quantitative breast-imaging tools, radiologists will be able to evaluate the performance of all major digital mammography and tomosynthesis units and obtain patient-specific dose information to make informed treatment decisions in real time.

“Today’s healthcare environment is increasingly data-driven and our customers require up-to-the-minute access to analytics that impact patient care,” said Ken Ferry, CEO of iCAD. “By incorporating additional breast imaging analytic and reporting solutions from Volpara, our PowerLook AMP customers will be able to go beyond automated mammography unit settings and mine patient-specific, real-time information for actionable insights regarding care delivery within their practices and across patient populations.”

PowerLook AMP is a next-generation digital mammography computer-aided detection (CAD) platform that provides radiologists with the ability to customize their 2-D CAD solution to meet the needs of their individual work environment. Now with the option to incorporate VolparaAnalytics and VolparaDose in addition to VolparaDensity, PowerLook AMP users will, among other benefits, be able to:

  • Improve patient safety and reporting through personalized measurements of density, patient dose, breast compression and other volumetric factors designed to help maintain accuracy and consistent quality in breast screening.
  • Optimize performance/utilization of staff and mammography systems.
  • Utilize a globally-accepted algorithm incorporating breast density to generate patient-specific radiation dose estimates, which can be automatically entered in patient communications.

Cleared by the U.S. Food and Drug Administration (FDA), HealthCanada, the TGA and CE-marked, VolparaDensity is used by radiologists to objectively assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening. Highly correlated to breast magnetic resonance imaging (MR) assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories. To date, more than 3 million women have had their breast density analyzed using VolparaDensity.

For more information: www.icadmed.com

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
Veterans Integrated Service Network 19 Implements System-Wide Radiation Dose Monitoring
News | Radiation Dose Management | December 04, 2018
Agfa HealthCare announced it has collaborated in delivering a system-wide DoseMonitor automated software implementation...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...